SCHEMBL1428261

SCHEMBL1428261

O=C(O)N1CCCC(Nc2nc(Cl)nc3ccccc23)CC1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
OGG1 O15527 1/20 0.50
ACP1 P24666 3/20 0.48
PDE5A O76074 2/20 0.48
MERTK Q12866 4/20 0.47
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
HSP90AA1 P07900 1/20 0.46
TLR7 Q9NYK1 4/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 1/20 0.46
NTSR1 P30989 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CCR4 P51679 1/20 0.46
WHR1 P49842 1/20 0.45
GBA1 P04062 3/20 0.45
NSD2 O96028 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427753 0.95 KMT2A (0.49) OGG1ACP1PDE5AMERTKKMT2A
SCHEMBL2331315 0.88 CHEK2 (0.47) OGG1ACP1PDE5AMERTKKMT2A
SCHEMBL9911806 0.87 NSD2 (0.50) KMT2AMEN1MAPTHTTGBA1
SCHEMBL17614452 0.83 TLR7 (0.51) ACP1PDE5AMERTKKMT2AMEN1
SCHEMBL14256445 0.83 ACP1 (0.67) OGG1ACP1PDE5AMERTKKMT2A
SCHEMBL9911789 0.81 NSD2 (0.53) KMT2AMEN1MAPTHTTGBA1
SCHEMBL12988643 0.81 ACP1 (0.68) OGG1ACP1PDE5AMERTKKMT2A
SCHEMBL17557550 0.81 EHMT2 (0.47) KMT2AMEN1HTTNSD2
SCHEMBL17544631 0.80 ACP1 (0.65) OGG1ACP1PDE5AMERTKKMT2A
SCHEMBL23261502 0.79 EHMT2 (0.62) OGG1ACP1PDE5AKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193203-B2 Bicyclic compounds having activity at the CXCR4 receptor ALLERGAN, INC. (US) 2012-06-05 US disclosed
CN-102105463-A Bicyclic compounds active on the CXCR4 receptor ALLERGAN INC 2011-06-22 CN disclosed
EP-2300456-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR Allergan, Inc. (US) 2011-03-30 EP disclosed
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-12-17 US disclosed
WO-2009143058-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR ALLERGAN, INC. (US) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312305-A1 BICYCLIC COMPOUNDS HAVING ACTIVITY AT THE CXCR4 RECEPTOR CXCR4, CXCR2, CXCL12 OGG1 4094/4885ACP1 1225/4885PDE5A 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.